全文获取类型
收费全文 | 196篇 |
免费 | 8篇 |
学科分类
医药卫生 | 204篇 |
出版年
2023年 | 1篇 |
2021年 | 2篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2016年 | 2篇 |
2015年 | 8篇 |
2014年 | 3篇 |
2013年 | 8篇 |
2012年 | 13篇 |
2011年 | 17篇 |
2010年 | 9篇 |
2009年 | 4篇 |
2008年 | 8篇 |
2007年 | 9篇 |
2006年 | 10篇 |
2005年 | 10篇 |
2004年 | 8篇 |
2003年 | 7篇 |
2002年 | 11篇 |
2001年 | 6篇 |
2000年 | 6篇 |
1999年 | 2篇 |
1995年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1986年 | 1篇 |
1980年 | 1篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1976年 | 3篇 |
1975年 | 4篇 |
1974年 | 9篇 |
1973年 | 1篇 |
1971年 | 2篇 |
1970年 | 6篇 |
1969年 | 3篇 |
1967年 | 3篇 |
1964年 | 2篇 |
1961年 | 1篇 |
1960年 | 1篇 |
排序方式: 共有204条查询结果,搜索用时 15 毫秒
1.
Demetris A Adams D Bellamy C Blakolmer K Clouston A Dhillon AP Fung J Gouw A Gustafsson B Haga H Harrison D Hart J Hubscher S Jaffe R Khettry U Lassman C Lewin K Martinez O Nakazawa Y Neil D Pappo O Parizhskaya M Randhawa P Rasoul-Rockenschaub S Reinholt F Reynes M Robert M Tsamandas A Wanless I Wiesner R Wernerson A Wrba F Wyatt J Yamabe H 《Hepatology (Baltimore, Md.)》2000,31(3):792-799
2.
John S. Millar Gissette Reyes-Soffer Patricia Jumes Richard L. Dunbar Emil M. deGoma Amanda L. Baer Wahida Karmally Daniel S. Donovan Hashmi Rafeek Laura Pollan Junichiro Tohyama Amy O. Johnson-Levonas John A. Wagner Stephen Holleran Joseph Obunike Yang Liu Rajasekhar Ramakrishnan Michael E. Lassman David E. Gutstein Henry N. Ginsberg Daniel J. Rader 《The Journal of clinical investigation》2015,125(6):2510-2522
BACKGROUND. Individuals treated with the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib exhibit a reduction in both LDL cholesterol and apolipoprotein B (ApoB) in response to monotherapy or combination therapy with a statin. It is not clear how anacetrapib exerts these effects; therefore, the goal of this study was to determine the kinetic mechanism responsible for the reduction in LDL and ApoB in response to anacetrapib.METHODS. We performed a trial of the effects of anacetrapib on ApoB kinetics. Mildly hypercholesterolemic subjects were randomized to background treatment of either placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks. All subjects then added 100 mg anacetrapib to background treatment for 8 weeks. Following each study period, subjects underwent a metabolic study to determine the LDL-ApoB-100 and proprotein convertase subtilisin/kexin type 9 (PCSK9) production rate (PR) and fractional catabolic rate (FCR).RESULTS. Anacetrapib markedly reduced the LDL-ApoB-100 pool size (PS) in both the placebo and ATV groups. These changes in PS resulted from substantial increases in LDL-ApoB-100 FCRs in both groups. Anacetrapib had no effect on LDL-ApoB-100 PRs in either treatment group. Moreover, there were no changes in the PCSK9 PS, FCR, or PR in either group. Anacetrapib treatment was associated with considerable increases in the LDL triglyceride/cholesterol ratio and LDL size by NMR.CONCLUSION. These data indicate that anacetrapib, given alone or in combination with a statin, reduces LDL-ApoB-100 levels by increasing the rate of ApoB-100 fractional clearance.TRIAL REGISTRATION. ClinicalTrials.gov .FUNDING. Merck & Co. Inc., Kenilworth, New Jersey, USA. Additional support for instrumentation was obtained from the National Center for Advancing Translational Sciences (UL1TR000003 and UL1TR000040). NCT00990808相似文献
3.
4.
van den Bent Martin Azaro Analia De Vos Filip Sepulveda Juan Yung W. K. Alfred Wen Patrick Y. Lassman Andrew B. Joerger Markus Tabatabai Ghazaleh Rodon Jordi Tiedt Ralph Zhao Sylvia Kirsilae Tiina Cheng Yi Vicente Sergio Balbin O. Alejandro Zhang Hefei Wick Wolfgang 《Journal of neuro-oncology》2020,146(1):79-89
Journal of Neuro-Oncology - To estimate the maximum tolerated dose (MTD) and/or identify the recommended Phase II dose (RP2D) for combined INC280 and buparlisib in patients with recurrent... 相似文献
5.
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation 总被引:28,自引:0,他引:28
Lu DS Yu NC Raman SS Lassman C Tong MJ Britten C Durazo F Saab S Han S Finn R Hiatt JR Busuttil RW 《Hepatology (Baltimore, Md.)》2005,41(5):1130-1137
Orthotopic liver transplantation (OLT) can be a definitive treatment for patients with hepatocellular carcinoma (HCC). Prolonged waiting times for cadaveric livers, however, may lead to dropout from the waiting list or worsened post-OLT prognosis as a result of interval tumor progression. Percutaneous radiofrequency ablation (RFA) is widely used for local control of small unresectable HCC, but its pretransplant role remains unclear. We studied the outcome of 52 consecutive patients accepted for OLT bearing 87 HCC nodules and treated with percutaneous RFA. On initial staging, the tumor burden exceeded the Milan criteria in 10 patients. Complete tumor coagulation was observed in 74 of 87 (85.1%) nodules based on postablation imaging. After a mean of 12.7 months (range: 0.3-43.5) on the waiting list, 3 of 52 patients (5.8%) had dropped out due to tumor progression. Forty-one patients had undergone transplantation, with 1- and 3-year post-OLT survival rates of 85% and 76%, respectively. No patient developed HCC recurrence. There were three major complications in 76 RFA procedures (hepatic arterial hemorrhage, small bowel perforation, and liver decompensation salvaged by OLT), without resultant death or dropout. In conclusion, percutaneous RFA is an effective bridge to OLT for patients with compensated liver function and safely accessible tumors. Tumor-related dropout rate and post-OLT outcome compared favorably with published controls of patients with early-stage disease. This can be attributed to the efficacy of RFA in producing local cure or curbing tumor progression during the waiting period. 相似文献
6.
7.
8.
9.
Cameron AM Truty J Truell J Lassman C Zimmerman MA Kelly BS Farmer DG Hiatt JR Ghobrial R Busuttil RW 《Transplantation》2005,80(7):993-996
Systemic lymphomas may involve the liver but rarely cause fulminant hepatic failure (FHF). Acute liver failure from primary hepatic lymphoma (PHL) is even less common with most patients succumbing to the sequelae of FHF before the correct diagnosis is made. We report a patient who underwent successful orthotopic liver transplant (OLT) and chemotherapy for FHF secondary to PHL. This previously-well male developed profound coagulopathy and encephalopathy 6 weeks after the onset of jaundice and fatigue. Workup failed to reveal the underlying cause of his liver failure and the patient soon required urgent OLT. Pathologic evaluation of his explanted liver revealed a malignant T-cell rich, large B-cell non-Hodgkin's lymphoma with widespread hepatocellular necrosis. The patient made an excellent clinical recovery and is undergoing CHOP-Rituxan chemotherapy. This scenario demonstrates that lymphoma should be considered in the differential diagnosis of FHF without clear etiology because of the potential for intervention with transplant and chemotherapy. 相似文献
10.
Farmer DG Anselmo D Da Shen X Ke B Carmody IC Gao F Lassman C McDiarmid SV Shaw G Busuttil RW Kupiec-Weglinski JW 《Transplantation》2005,80(6):828-835
BACKGROUND: This study analyzes the role of T lymphocytes and neutrophils (PMN) in intestinal ischemia and reperfusion injury (IRI) using either P-selectin blockade or elimination. METHODS: Using a model of severe mouse warm intestinal IRI, the following groups were performed: group 1: wild type C57BL6 no treatment; group 2: wild type treated with r-PSGL1-Ig; group 3: C57BL6 genetically deficient in P-selectin. Survival was assessed at day 7; intestine was assayed for histopathology, apoptosis, myeloperoxidase (MPO), inflammatory cytokines, hemoxygenase-1 (HO-1), and CD3 lymphocytes. Standard statistical comparison was undertaken. RESULTS: The survival was significantly (P < 0.01) improved in the treatment groups: group 1, 50%; group 2, 90%; group 3, 100%. Graded histopathology and crypt apoptosis were improved in groups 2 and 3. MPO and CD3 positive cells were significantly reduced in groups 2 and 3. A significant reduction in inflammatory/Th1-type cytokines was seen in groups 2 and 3 as compared to group 1. Conversely, a significant increase in Th2-type cytokines and HO-1 production was seen selectively in groups 2 and 3. CONCLUSIONS: This study demonstrates the importance of P-selectin signaling in warm, murine intestinal IRI in that either the blockade of or the genetic deficiency in P-selectin confers a survival advantage and reduction in tissue injury/inflammation. The mechanism involves a reduction of PMN and CD3 T cell infiltration and an alteration in the cytokine microenvironment in favor of a Th2 profile. These data implicate T lymphocyte as an important regulatory cell in this inflammatory process. 相似文献